A novel proteasome inhibitor NPI-0052 as an anticancer therapy

British Journal of Cancer

Volumn 95, Issue 8, 2006, Pages 961-965

  Chauhan, D ^a   Hideshima, T ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Drug resistance; Multiple myeloma; Novel therapy; Proteasomes; Protein degradation

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; LACTACYSTIN BETA LACTONE; NPI 0052; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LACTONES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750209537     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603406     Document Type: Short Survey

References (36)

1. Adams J (2002) Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6: 493-500
2. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360
3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622
4. Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM (2005) Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 65: 7896-7901
5. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ (2005) Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2: 357-362
6. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, Lopez-Holgado N, Maiso P, Alberca M, Villaron E, Schenkein D, Pandiella A, San Miguel J (2006) Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107: 3575-3583
7. Cardozo C (1993) Catalytic components of the bovine pituitary multicatalytic proteinase complex (proteasome). Enzyme Protein 47: 296-305
8. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC (2005a) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8: 407-419
9. Chauhan D, Hideshima T, Anderson KC (2005b) Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45: 465-476
10. Ciechanover A (2003) The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 31: 474-481
11. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95: 2727-2730
12. Corey EJ, Li WD (1999) Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull (Tokyo) 47: 1-10
13. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE (2006) Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 66: 6379-6386
14. Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM (2000) Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303: 643-653
15. Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116: 637-646
16. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42: 355-357
17. Goldberg AL, Rock K (2002) Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8: 338-340
18. Groll M, Huber R, Potts BC (2006) Crystal structures of salinosporamide A (npi-0052) and b (npi-0047) in complex with the 20s proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128: 5136-5141
19. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23: 6107-6116
20. Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937
21. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dong L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 28: 28
22. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS (2001) Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol 8: 913-929
23. Kisselev AF, Callard A, Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281: 8582-8590
24. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000
25. Lupas A, Koster AJ, BaumeisterW (1993) Structural features of 26S and 20S proteasomes. Enzyme Protein 47: 252-273
26. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, Deyanat-Yazdi G, Mai B, Jensen PR, Fenical WF, Neuteboom ST, Lam KS, Palladino MA, Potts BC (2005) Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48: 3684-3687
27. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245-273
28. Oberdorf J, Carlson EJ, Skach WR (2001) Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation. Biochemistry 40: 13397-13405
29. Orlowski M, Cardozo C, Michaud C (1993) Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32: 1563-1572
30. Pickart CM (2004) Back to the future with ubiquitin. Cell 116: 181-190
31. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent pkcalpha activation. J Biol Chem 277: 7875-7881
32. Richardson PG (2004) A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5: 1321-1331
33. Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P, Cusack Jr JC (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193
34. Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27: 157-162
35. Stohwasser R, Standera S, Peters I, Kloetzel PM, Groettrup M (1997) Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits. Eur J Immunol 27: 1182-1187
36. Uebel S, Tampe R (1999) Specificity of the proteasome and the TAP transporter. Curr Opin Immunol 11: 203-208